Treosulfan in the treatment of metastatic renal cell carcinoma.

Abstract

BACKGROUND:

Treosulfan is a bifunctional alkylating cytostatic agent that has mainly been used in the therapy of advanced ovarian cancer. Lately, a growth inhibiting effect could be detected in human renal cell carcinoma-cell lines as well. In vitro, Treosulfan showed an even higher growth inhibition than Vinblastine.

MATERIALS AND METHODS:

We performed a small clinical phase II study using Treosulfan as a monotherapy in the treatment of metastatic renal cell carcinoma. Treosulfan was given to 15 patients with bidimensionally measurable metastases.

RESULTS:

10 patients were evaluable. Side effects were negligeable. A complete or even partial remission was not seen. 4 patients showed no change, whereas 6 were progressive. The average time to progress was short (4 months, range 1 to 12 months).

CONCLUSIONS:

Since Treosulfan did not lead to a measurable tumor remission in the given dose regimen, it does not seem to be suitable for the therapy of metastatic renal cell carcinoma.

• Authors: D Rigos, H W Wechsel, K H Bichler
• Journal: Anticancer research (Anticancer Res) 1999 Mar-Apr Vol. 19 Issue 2C Pg. 1549-52 ISSN: 0250-7005 [Print] Greece
• PMID: 10365143 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)

Chemical References

• Antineoplastic Agents, Alkylating
• treosulfan
• Busulfan

Topics

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Agents, Alkylating (adverse effects, therapeutic use)
• Busulfan (adverse effects, analogs & derivatives, therapeutic use)
• Carcinoma, Renal Cell (drug therapy, pathology)
• Disease-Free Survival
• Humans
• Kidney Neoplasms (drug therapy, pathology)
• Middle Aged
• Neoplasm Metastasis
• Neoplasm Staging
• Time Factors